Through the utilization of the latest advancements in human genetics, Genessense enables individuals to understand how their DNA can influence the likelihood of developing various diseases, including heart disease, diabetes, and hypertension. At Genessense, our team of scientists has dedicated over 10,000 man-hours to research and validation studies, collaborating with esteemed institutions such as Harvard, to craft a scientifically proven portfolio of Genomic Wellness Services. One pivotal aspect in this realm is the Polygenic Risk Score (PRS), a globally recognized marker that plays a crucial role in predicting disease risk early on.

Polygenic Risk Score (PRS) serves as a valuable indicator, contributing to the overall efficacy of our genomic screening services. This revolutionary technology allows for the prediction of disease risks far earlier than traditional clinical screening tests. Genessense provides a comprehensive array of genetic screening options for preventive wellness, encompassing:

• Polygenic risk score-based screening
• Inherited cancer screening
• Carrier screening
• Pharmacogenomics
• Biological and Pace of aging estimation

Genessense, developed by MedGenome, stands as a flagship offering from India's leading Genetic Diagnostics and Genomics Research company. MedGenome has established itself as a pioneer in genetic testing within India and South Asia, operating the largest CAP-accredited Genetic and DNA sequencing lab. With a core mission to enhance global health by gaining profound insights into diseases at the genetic and molecular level, MedGenome leverages cutting-edge technologies in genomics and science-driven approaches.